FGF23 induces left ventricular hypertrophy

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369

Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology

Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart study

Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699

Prevalence of Chronic Kidney Disease in the United States

Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837

A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy

Molkentin, J. D., Lu, J., Antos, C. L., Markham, B. E., Richardson, J. A., Robbins, J. M., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566

Fibroblast growth factors.

Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985

Cellular signaling by fibroblast growth factor receptors

Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,923

Regulation of cardiac hypertrophy by intracellular signalling pathways

Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,890

Receptor Specificity of the Fibroblast Growth Factor Family

Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., & Goldfarb, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15292 · Cited by 1,871

FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis

Böckmann, I., Lischka, J., Richter, B., Deppe, J., Rahn, A., Fischer, D., Heineke, J., Haffner, D., & Leifheit‐Nestler, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184634 · Cited by 106

Fibroblast growth factor 23 and bone mineralisation

Guo, Y.-C., & Yuan, Q. (2015) · International Journal of Oral Science · doi:10.1038/ijos.2015.1 · Cited by 105

Fibroblast growth factor 23 is induced by an activated renin–angiotensin–aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts

Leifheit‐Nestler, M., Kirchhoff, F., Nespor, J., Richter, B., Soetje, B., Klintschar, M., Heineke, J., & Haffner, D. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy006 · Cited by 105

Npt2b Deletion Attenuates Hyperphosphatemia Associated with CKD

Schiavi, S. C., Tang, W., Bracken, C., O’Brien, S. P., Song, W., Boulanger, J., Ryan, S., Phillips, L. A., Liu, S., ARBEENY, C. M., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011121213 · Cited by 103

Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial

Ix, J. H., Isakova, T., Larive, B., Raphael, K. L., Raj, D. S., Cheung, A. K., Sprague, S. M., Fried, L. F., Gassman, J., Middleton, J. P., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018101058 · Cited by 103

Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors

Moody, W. E., Ferro, C. J., Edwards, N. C., Chue, C. D., Lin, E. L. S., Taylor, R. J., Cockwell, P., Steeds, R. P., & Townend, J. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06608 · Cited by 103

Approach to Treatment of Hypophosphatemia

Felsenfeld, A. J., & Levine, B. S. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.03.024 · Cited by 102

Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population

Chia, Y. C., Kieneker, L. M., van Hassel, G., Binnenmars, S. H., Nolte, I. M., van Zanden, J. J., van der Meer, P., Navis, G. J., Voors, A. A., Bakker, S. J. L., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018549 · Cited by 115

Impaired Vitamin D Metabolism in CKD

Bosworth, C., & de Boer, I. H. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.12.016 · Cited by 102

The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia

Czaya, B. A., & Faul, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174195 · Cited by 101

Lupus nephritis-related chronic kidney disease

Lichtnekert, J., & Anders, H. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01158-w · Cited by 103

Heart Rate Variability Is a Predictor of Mortality in Chronic Kidney Disease: A Report from the CRIC Study

Drawz, P. E., Babineau, D. C., Brecklin, C. S., He, J., Kallem, R. R., Soliman, E. Z., Xie, D., Appleby, D. H., Anderson, A. H., Rahman, M., et al. (2013) · American Journal of Nephrology · doi:10.1159/000357200 · Cited by 99

Arterial Stiffness, Central Pressures, and Incident Hospitalized Heart Failure in the Chronic Renal Insufficiency Cohort Study

Chirinos, J. A., Khan, A. M., Bansal, N., Dries, D. L., Feldman, H. I., Ford, V., Anderson, A. H., Kallem, R. R., Lash, J. P., OJO, A. O., et al. (2014) · Circulation Heart Failure · doi:10.1161/circheartfailure.113.001041 · Cited by 99

Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor

Zanchi, C., Locatelli, M., Benigni, A., Corna, D., Tomasoni, S., Rottoli, D., Gaspari, F., Remuzzi, G., & Zoja, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070775 · Cited by 98

Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations

Law, J. P., Pickup, L. C., Pavlović, D., Townend, J., & Ferro, C. J. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-022-00751-4 · Cited by 111

Acute kidney injury and distant organ dysfunction–network system analysis

Matsuura, R., Doi, K., & Rabb, H. (2023) · Kidney International · doi:10.1016/j.kint.2023.03.025 · Cited by 100

Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica: 2021 (SEN-MM)

Torregrosa, J., Bover, J., Rodríguez, M., Parra, E. G., Jiménez, M. D. A., Caravaca, F., Casaus, M.-L. G., Martín-Malo, A., Navarro-González, J. F., Lorenzo, V., et al. (2022) · Nefrología · doi:10.1016/j.nefro.2022.03.007 · Cited by 111

Effects of phosphate on vascular function under normal conditions and influence of the uraemic state

Six, I., Maizel, J., Barreto, F. C., Rangrez, A. Y., Dupont, S., Slama, M., Tribouilloy, C. M., Choukroun, G. J., Mazière, J., Bode‐Böger, S. M., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs240 · Cited by 99

FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts

Smith, E. R., Tan, S., Holt, S. G., & Hewitson, T. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-02709-w · Cited by 97

FGF-23 Levels in Patients with AKI and Risk of Adverse Outcomes

Leaf, D. E., Wolf, M. S., Waikar, S. S., Chase, H. S., Christov, M., Cremers, S., & Stern, L. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00550112 · Cited by 97

DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease

Dussold, C., Gerber, C., White, S., Wang, X., Qi, L., Francis, C., Capella, M., Courbon, G., Wang, J., Li, C., et al. (2019) · Bone Research · doi:10.1038/s41413-019-0051-1 · Cited by 96

Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans

Zhu, Y., Prata, L. G. P. L., Gerdes, E. O. W., Netto, J. M. E., Pirtskhalava, T., Giorgadze, N., Tripathi, U., Inman, C. L., Johnson, K. O., Xue, A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103912 · Cited by 100

Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets?

Palomer, X., Pizarro‐Delgado, J., & Vázquez‐Carrera, M. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.02.010 · Cited by 96

FGF23 and Phosphate–Cardiovascular Toxins in CKD

Vogt, I., Haffner, D., & Leifheit‐Nestler, M. (2019) · Toxins · doi:10.3390/toxins11110647 · Cited by 100

The role of FGF23 in CKD—with or without Klotho

Komaba, H., & Fukagawa, M. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.116 · Cited by 99

Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease

Egli-Spichtig, D., Zhang, H., Mohebbi, N., Pavik, I., Petzold, K., Stange, G., Saleh, L., Edenhofer, I., Segerer, S., Biber, J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.526 · Cited by 95

Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease

Udell, J. A., Morrow, D. A., Jarolím, P., Sloan, S., Hoffman, E. B., O’Donnell, T. F. X., Vora, A. N., Omland, T., Solomon, S. D., Pfeffer, M. A., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.026 · Cited by 95

Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery

Leaf, D. E., Christov, M., Jüppner, H., Siew, E. D., Ikizler, T. A., Bian, A., Chen, G., Sabbisetti, V. S., Bonventre, J. V., Cai, X., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.035 · Cited by 95

Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness

Leaf, D. E., Jacob, K. A., Srivastava, A., Chen, M. E., Christov, M., Jüppner, H., Sabbisetti, V. S., Martin, A., Wolf, M. S., & Waikar, S. S. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016080836 · Cited by 95

FGF23 and Left Ventricular Hypertrophy in Children with CKD

Mitsnefes, M. M., Betoko, A. S., Schneider, M. F., Salusky, I. B., Wolf, M. S., Jüppner, H., Warady, B. A., Furth, S. L., & Portale, A. A. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02110217 · Cited by 95

Effects of erythropoietin on fibroblast growth factor 23 in mice and humans

Hanudel, M. R., Eisenga, M. F., Rappaport, M. D., Chua, K. J., Qiao, B., Jung, G., Gabayan, V. R., Gales, B., Ramos, G., de Jong, M. A., et al. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy189 · Cited by 95

Klotho/FGF23 and Wnt Signaling as Important Players in the Comorbidities Associated with Chronic Kidney Disease

Muñoz-Castañeda, J. R., Rodelo‐Haad, C., de Mier, M. V. P.-R., Martín‐Malo, A., Santamaría, R., & Rodríguez, M. (2020) · Toxins · doi:10.3390/toxins12030185 · Cited by 102

Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets

van de Wouw, J., Broekhuizen, M., Sorop, O., Joles, J. A., Verhaar, M. C., Duncker, D. J., Danser, A. H. J., & Merkus, D. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01108 · Cited by 97

Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD

Marco, G. S. D., Reuter, S., Kentrup, D., Grabner, A., Amaral, A. P., Fobker, M., Stypmann, J., Pavenstädt, H., Wolf, M. S., Faul, C., et al. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu190 · Cited by 92

Role of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders

Workgroup, O. B. O. T. E. R. O. (., Carrillo-López, N., Martínez-Arias, L., Fernández-Villabrille, S., Ruiz-Torres, M. P., Dusso, A., Cannata-Andía, J. B., Naves-Díaz, M., & Panizo, S. (2021) · Calcified Tissue International · doi:10.1007/s00223-020-00803-2 · Cited by 91

Up-regulation of FGF23 release by aldosterone

Zhang, B., Umbach, A. T., Chen, H., Yan, J., Fakhri, H., Fajol, A., Salker, M. S., Spichtig, D., Daryadel, A., Wagner, C. A., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.034 · Cited by 91

Interpreting Cardiac Biomarkers in the Setting of Chronic Kidney Disease

deFilippi, C. R., & Herzog, C. A. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.254748 · Cited by 91

New Insights Into the FGF23-Klotho Axis

Olauson, H., Vervloet, M. G., Cozzolino, M. G., Massy, Z. A., Ureña, P., & Larsson, T. E. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.09.005 · Cited by 90

Expression of Fgf23 in Activated Dendritic Cells and Macrophages in Response to Immunological Stimuli in Mice

Masuda, Y., Ohta, H., Morita, Y., Nakayama, Y., Miyake, A., Itoh, N., & Konishi, M. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00276 · Cited by 90

Fibroblast growth factor 23 (FGF23) and mortality: The Ludwigshafen Risk and Cardiovascular Health Study

Brandenburg, V. M., Kleber, M. E., Vervloet, M. G., Tomaschitz, A., Pilz, S., Stojaković, T., Delgado, G., Grammer, T. B., Marx, N., März, W., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.08.037 · Cited by 89

Cisplatin nephrotoxicity as a model of chronic kidney disease

Shi, M., McMillan, K. L., Wu, J., Gillings, N., Flores, B., Moe, O. W., & Hu, M. C. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0063-2 · Cited by 94

Uremic Toxins and Vascular Dysfunction

Six, I., Flissi, N., Lenglet, G., Louvet, L., Kamel, S., Gallet, M., Massy, Z. A., & Liabeuf, S. (2020) · Toxins · doi:10.3390/toxins12060404 · Cited by 97

Fractional Excretion of Phosphorus Modifies the Association between Fibroblast Growth Factor-23 and Outcomes

Dominguez, J. R., Shlipak, M. G., Whooley, M. A., & Ix, J. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012090894 · Cited by 88

Long–term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis

Chen, L., Wang, K., Yu, S., Lai, L., Zhang, X., Yuan, J., & Duan, W. (2016) · Renal Failure · doi:10.1080/0886022x.2016.1184924 · Cited by 88

Experimental Myocardial Infarction Upregulates Circulating Fibroblast Growth Factor-23

Andrukhova, O., Slavić, S., Odörfer, K. I., & Erben, R. G. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2527 · Cited by 88

Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats

Leifheit‐Nestler, M., Grabner, A., Hermann, L. L., Richter, B., Schmitz, K., Fischer, D.-C., Yanucil, C., Faul, C., & Haffner, D. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw454 · Cited by 89

Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis

Memmos, E., Sarafidis, P. A., Pateinakis, P., Tsiantoulas, A., Faitatzidou, D., Giamalis, P., Vasilikos, V., & Papagianni, A. A. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1391-1 · Cited by 87

Nutritional management in patients with chronic kidney disease

Kim, S. M., & Jung, J. Y. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.408 · Cited by 112

Effects of frequent hemodialysis on ventricular volumes and left ventricular remodeling.

Chan, C. T., Greene, T., Chertow, G., Kliger, A., Stokes, J., Beck, G., Daugirdas, J., Kotanko, P., Larive, B., Levin, N., et al. (2013) · American Society of Nephrology. Clinical Journal · doi:10.2215/cjn.03280313 · Cited by 78

Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study

Souma, N., Isakova, T., Lipiszko, D., Sacco, R. L., Elkind, M. S. V., DeRosa, J. T., Silverberg, S. J., Mendez, A. J., Dong, C., Wright, C. B., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2215 · Cited by 87

Disorders of Iron Metabolism and Anemia in Chronic Kidney Disease

Panwar, B., & Gutiérrez, O. M. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.05.002 · Cited by 87

FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?

Stöhr, R., Schuh, A., Heine, G. H., & Brandenburg, V. M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00351 · Cited by 86

Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis

The J-DAVID Investigators, Shoji, T., Inaba, M., Fukagawa, M., Ando, R., Emoto, M., Fujii, H., Fujimori, A., Fukui, M., Hase, H., et al. (2018) · JAMA · doi:10.1001/jama.2018.17749 · Cited by 88

Sodium- and Phosphorus-Based Food Additives: Persistent but Surmountable Hurdles in the Management of Nutrition in Chronic Kidney Disease

Gutiérrez, O. M. (2013) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.10.008 · Cited by 96

In vivo evidence for a limited role of proximal tubular Klotho in renal phosphate handling

Ide, N., Olauson, H., Sato, T., Densmore, M., Wang, H., Hanai, J., Larsson, T. E., & Lanske, B. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.009 · Cited by 86

Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting

Bacchetta, J., Bardet, C., & Prié, D. (2019) · Metabolism · doi:10.1016/j.metabol.2019.01.006 · Cited by 85

Large uremic toxins: an unsolved problem in end-stage kidney disease

Wolley, M. J., & Hutchison, C. A. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy179 · Cited by 85

Chronic Kidney Disease: Mineral and Bone Disorder in Children

Wesseling‐Perry, K., & Salusky, I. B. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.12.017 · Cited by 84

Atrial Fibrillation and Endothelial Dysfunction

Corban, M., Toya, T., Ahmad, A., Lerman, L. O., Lee, H.-C., & Lerman, A. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.11.005 · Cited by 87

Phosphorus and Risk of Renal Failure in Subjects with Normal Renal Function

Sim, J. J., Bhandari, S. K., Smith, N. X., Chung, J., Liu, I. L. A., Jacobsen, S. J., & Kalantar‐Zadeh, K. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.08.018 · Cited by 84

Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients

Iorio, B. R. D., Bellizzi, V., Bellasi, A., Torraca, S., D’Arrigo, G., Tripepi, G. L., & Zoccali, C. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs477 · Cited by 84

A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD

Block, G. A., Block, M. S., Smits, G., Mehta, R. C., Isakova, T., Wolf, M. S., & Chertow, G. M. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018101016 · Cited by 85

Inflammation: a putative link between phosphate metabolism and cardiovascular disease

Voelkl, J. G. J., Egli-Spichtig, D., Alesutan, I., & Wagner, C. A. (2021) · Clinical Science · doi:10.1042/cs20190895 · Cited by 83

Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults

Jovanovich, A. J., Ix, J. H., Gottdiener, J. S., McFann, K., Katz, R., Kestenbaum, B. R., de Boer, I. H., Sarnak, M. J., Shlipak, M. G., Mukamal, K. J., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.09.002 · Cited by 83

Impact of Phosphorus-Based Food Additives on Bone and Mineral Metabolism

Gutiérrez, O. M., Luzuriaga-McPherson, A., Lin, Y., Gilbert, L. C., Ha, S.-W., & Beck, G. R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2279 · Cited by 82

Iron and Heart Failure

Ghafourian, K., Shapiro, J. S., Goodman, L., & Ardehali, H. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.08.009 · Cited by 85

Hyperphosphatemia and Cardiovascular Disease

Zhou, C., Shi, Z., Ouyang, N., & Ruan, X. Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.644363 · Cited by 89

Phosphate is a vascular toxin

Shroff, R. C. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2347-x · Cited by 81

Association between Inflammation and Cardiac Geometry in Chronic Kidney Disease: Findings from the CRIC Study

Gupta, J., Dominic, E. A., Fink, J. C., OJO, A. O., Barrows, I. R., Reilly, M. P., Townsend, R. R., Joffe, M. M., Rosas, S. E., Wolman, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124772 · Cited by 82

A Comparison of Calcium to Zoledronic Acid for Improvement of Cortical Bone in an Animal Model of CKD

Moe, S. M., Chen, N. X., Newman, C. L., Gattone, V. H., Organ, J. M., Chen, X., & Allen, M. R. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2089 · Cited by 82

Serum Level of the Phosphaturic Factor FGF23 Is Associated with Abdominal Aortic Calcification in Men: The STRAMBO Study

Schoppet, M., Hofbauer, L. C., Brinskelle-Schmal, N., Varennes, A., Goudable, J., Richard, M., Hawa, G., Chapurlat, R. D., & Szulc, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2836 · Cited by 81

Non-Systemic Drugs: A Critical Review

Charmot, D. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799504858 · Cited by 83

Biology of Fibroblast Growth Factor 23: From Physiology to PathologyPreprint

Courbebaisse, M., & Lanske, B. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031260 · Cited by 81

Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study

Bansal, N., Zelnick, L. R., Go, A., Anderson, A. H., Christenson, R., Deo, R., Defilippi, C., Lash, J., He, J., Ky, B., et al. (2019) · Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease · doi:10.1161/jaha.119.012336 · Cited by 76

FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice

Han, X., Cai, C., Xiao, Z., & Quarles, L. D. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.11.149 · Cited by 82

Empagliflozin restores chronic kidney disease–induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction

Juni, R. P., Al‐Shama, R., Kuster, D. W. D., van der Velden, J., Hamer, H. M., Vervloet, M. G., Eringa, E. C., Koolwijk, P., & van Hinsbergh, V. W. M. (2020) · Kidney International · doi:10.1016/j.kint.2020.12.013 · Cited by 79

Cardiorenal syndrome: clinical diagnosis, molecular mechanisms and therapeutic strategies

Zhao, B., Hu, X., Wang, W., & Zhou, Y. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01476-z · Cited by 91

Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis

Nakano, C., Hamano, T., Fujii, N., Obi, Y., Matsui, I., Tomida, K., Mikami, S., Inoue, K., Shimomura, A., Nagasawa, Y., et al. (2012) · Bone · doi:10.1016/j.bone.2012.02.634 · Cited by 81

FGF-23 Regulates CYP27B1 Transcription in the Kidney and in Extra-Renal Tissues

Chanakul, A., Zhang, M. Y. H., Louw, A., Armbrecht, H. J., Miller, W. L., Portale, A. A., & Perwad, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072816 · Cited by 80

Klotho and endocrine fibroblast growth factors: markers of chronic kidney disease progression and cardiovascular complications?

Kuro-o, M. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy126 · Cited by 80

Serum Parathyroid Hormone and 25‐Hydroxyvitamin D Concentrations and Risk of Incident Heart Failure: The Multi‐Ethnic Study of Atherosclerosis

Bansal, N., Zelnick, L. R., Robinson‐Cohen, C., Hoofnagle, A. N., Ix, J. H., Lima, J. A. C., Shoben, A. B., Peralta, C. A., Siscovick, D. S., Kestenbaum, B. R., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001278 · Cited by 80

Phosphate is a potential biomarker of disease severity and predicts adverse outcomes in acute kidney injury patients undergoing continuous renal replacement therapy

Jung, S.-Y., Kwon, J., Park, S., Jhee, J. H., Yun, H., Kim, H., Kee, Y. K., Yoon, C.-Y., Chang, T. I., Kang, E. W., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191290 · Cited by 79

Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study

Ix, J. H., Anderson, C. A. M., Smits, G., Persky, M. S., & Block, G. A. (2014) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.085498 · Cited by 79

FGF23, Albuminuria, and Disease Progression in Patients with Chronic IgA Nephropathy

Lundberg, S. G. G., Qureshi, A. R., Olivecrona, S., Gunnarsson, I., Jacobson, S. H., & Larsson, T. E. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10331011 · Cited by 79

Biomarkers of Vascular Calcification and Mortality in Patients with ESRD

Scialla, J. J., Kao, W. H. L., Crainiceanu, C., Sozio, S. M., Oberai, P. C., Shafi, T., Coresh, J., Powe, N. R., Plantinga, L., Jaar, B. G., et al. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05450513 · Cited by 79

The Cardiovascular Burden in End-Stage Renal Disease

Cozzolino, M. G., Galassi, A., Pivari, F., Ciceri, P., & Conte, F. (2017) · Contributions to nephrology · doi:10.1159/000479250 · Cited by 79

Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism

Sprague, S. M., Wetmore, J. B., Gurevich, K., da Roza, G., Buerkert, J. E., Reiner, M. T., Goodman, W. G., & Cooper, K. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03270314 · Cited by 78

Phosphate Homeostasis in CKD: Report of a Scientific Symposium Sponsored by the National Kidney Foundation

Block, G. A., Ix, J. H., Ketteler, M., Martin, K. J., Thadhani, R., Tonelli, M. A., Wolf, M. S., Jüppner, H., Hruska, K. A., & Wheeler, D. C. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.03.042 · Cited by 81

Phosphate control in end-stage renal disease: barriers and opportunities

Waheed, A. A., Pedraza, F., Lenz, O., & Isakova, T. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft244 · Cited by 78

FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase

Flamme, I., Ellinghaus, P., Urrego, D., & Krüger, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186979 · Cited by 77

Renal-Cardiac Crosstalk in the Pathogenesis and Progression of Heart Failure

Noels, H., van der Vorst, E. P. C., Rubin, S., Emmett, A., Marx, N., Tomaszewski, M., & Jankowski, J. (2025) · Circulation Research · doi:10.1161/circresaha.124.325488 · Cited by 92

Fibroblast growth factor 23

Smith, E. R., McMahon, L. P., & Holt, S. G. (2013) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563213510708 · Cited by 78

Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study

Mehta, R. C., Cai, X., Hodakowski, A. J., Lee, J. J., Leonard, M. B., Ricardo, A. C., Chen, J., Hamm, L. L., Sondheimer, J., Dobre, M. A., et al. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03950417 · Cited by 78

Cardiorenal Syndrome in Acute Kidney Injury

Lullo, L. D., Reeves, P., Bellasi, A., & Ronco, C. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.10.003 · Cited by 77

Cardiovascular Disease in Children and Adolescents With Chronic Kidney Disease

Weaver, D. J., & Mitsnefes, M. M. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.08.002 · Cited by 76

Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation

Egli-Spichtig, D., Silva, P. H. I., Glaudemans, B., Gehring, N., Bettoni, C., Zhang, M. Y. H., Pastor‐Arroyo, E. M., Schönenberger, D., Rajski, M., Hoogewijs, D., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.04.009 · Cited by 76

Phosphate Balance and CKD–Mineral Bone Disease

Sprague, S. M., Martin, K. J., & Coyne, D. W. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.012 · Cited by 75

Cardiorenal Syndrome Type 4: Insights on Clinical Presentation and Pathophysiology from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI)

Tumlin, J. A., Costanzo, M. R., Chawla, L. S., Herzog, C. A., Kellum, J. A., McCullough, P. A., Ronco, C., & for the Acute Dialysis Quality Initiative (ADQI) 11 Consensus Group (2013) · Contributions to nephrology · doi:10.1159/000349972 · Cited by 76

The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk

Pastor‐Arroyo, E. M., Gehring, N., Krudewig, C., Costantino, S., Bettoni, C., Knöpfel, T., Sabrautzki, S., Lorenz‐Depiereux, B., Pastor, J. V., Strom, T. M., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.02.017 · Cited by 76

Effects of Phosphate Binder Therapy on Vascular Stiffness in Early-Stage Chronic Kidney Disease

Seifert, M. E., Fuentes, L. D. L., Rothstein, M., Dietzen, D. J., Bierhals, A. J., Cheng, S. C., Ross, W. R., Windus, D. W., Dávila‐Román, V. G., & Hruska, K. A. (2013) · American Journal of Nephrology · doi:10.1159/000353569 · Cited by 75

Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease

Leifheit‐Nestler, M., Siemer, R. G., Flasbart, K., Richter, B., Kirchhoff, F., Ziegler, W. H., Klintschar, M., Becker, J. U., Erbersdobler, A., Aufricht, C., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv421 · Cited by 207

Connecting the dots on fibroblast growth factor 23 and left ventricular hypertrophy

Gutiérrez, O. M. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv445 · Cited by 5

SaO027CARDIO-PATHOLOGICAL EFFECTS OF FGF23 IN CKD ARE MEDIATED BY FGFR4

Grabner, A., Amaral, A. P., Singh, S., Schramm, K. J., Sloan, A. J., Kentrup, D., Reuter, S., Pavenstaedt, H., Marco, G. S. D., Wolf, M., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv150.04

FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD

Hidaka, N., Inoue, K., Katô, H., Hoshino, Y., Koga, M., Kinoshita, Y., Takashi, Y., Makita, N., Fukumoto, S., Nangaku, M., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100747 · Cited by 13

Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease

Gutiérrez, O. M., Januzzi, J. L., Isakova, T., Laliberte, K. A., Smith, K., Collerone, G., Sarwar, A., Hoffmann, U., Coglianese, E. E., Christenson, R. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.844506 · Cited by 843